Alimera Sciences, Inc.
|Number of Estimates|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
Market Cap: 28.7 Million
Primary Exchange: NASDAQ
Shares Outstanding: 5.03 Million
Float: 4.12 Million
Sector: Health Technology
Longest drawdown: 1957 trading days
From: 2014-03-31 To: 2019-12-06
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|